Donepezil vs Memantine

How they're similar

Donepezil and memantine are both symptomatic treatments for Alzheimer's disease. They ease some symptoms while the disease continues underneath. Neither one modifies the disease, meaning neither slows or reverses the loss of neurons that's driving the decline.

• Both are taken every day and both need consistent use to keep any benefit going.
• Both show modest effect sizes in trials. On cognitive rating scales like ADAS-cog, the average improvement is about 3 to 4 points, and often what looks like a treatment effect is really stabilization for a period rather than a return of lost function.
• Both are commonly used in moderate to severe Alzheimer's, sometimes together.
• Both need to be tapered off carefully if they're stopped, because rapid changes can lead to a sharper drop in function.
• Both come in generic form, which keeps the cost reasonable for most families.

The overlap really is at the level of purpose. Two different drugs, two different mechanisms, aimed at the same problem, and each one giving a fairly small nudge in the right direction. Combining them can offer a somewhat larger benefit for people in the moderate to severe range.

How they differ

The mechanism is different, the approved stages are different, and the side effect profiles are different. The table sums up the core points.

Donepezil works by slowing the breakdown of acetylcholine, a chemical messenger that's lost early in Alzheimer's. When the enzyme acetylcholinesterase is blocked, more acetylcholine stays available at nerve endings. That extra availability is what modestly supports memory and attention.

Memantine works on a completely different system. Glutamate is the brain's main excitatory messenger, and in Alzheimer's, glutamate signaling through NMDA receptors seems to be running at a low chronic level of overactivity that damages neurons over time. Memantine is a low-affinity blocker of these receptors, meaning it dampens the chronic noise without shutting down the normal signals that are needed for learning.

Approved stages come from where each drug was studied. Donepezil is approved across the range of Alzheimer's from mild to severe. Memantine's evidence base is in the moderate to severe range, so that's where its approval sits. In practice, memantine is sometimes tried off-label earlier, but the strongest data for it is in more advanced disease.

Dosing is straightforward but each drug has its rhythm. Donepezil starts at 5 mg once daily, usually at bedtime, and after four to six weeks the dose is often raised to 10 mg. A 23 mg version exists for severe Alzheimer's, and it's a separate formulation, not two tablets combined. Memantine starts low at 5 mg daily and is titrated up by 5 mg each week to reach 10 mg twice daily, or 28 mg once daily in the extended release form. That slow titration is important for keeping side effects manageable.

Side effect tendencies

The side effects sit at the heart of the choice between these two.

Donepezil's side effects come from raising acetylcholine everywhere in the body, not just in the brain. That means the gut, the heart, and the sleep system all feel it. Nausea, diarrhea, decreased appetite, and weight loss are the ones families notice most. Slower heart rate is a real concern, especially in someone already on a beta-blocker or with a known conduction issue, and rarely it can cause fainting. Vivid dreams and nightmares happen for some people, which is one reason morning dosing is sometimes preferred if bedtime dosing is disturbing sleep. Muscle cramps and increased urination round out the common list. Most side effects show up early and either fade or lead to a dose adjustment. Some people just can't tolerate any cholinesterase inhibitor, and that's a normal outcome.

Memantine is much better tolerated overall. Dizziness is the most common complaint, and it usually settles as the dose is titrated. Headache, confusion, and constipation come up but aren't often severe. The confusion piece can be tricky, because it looks like the disease itself, and slowing down the titration usually helps. Memantine isn't cleared by the liver in the usual way, so it has fewer drug interactions to worry about. It is cleared by the kidneys, so the dose needs to be lowered in significant kidney disease.

Bradycardia and syncope are real reasons a prescriber might hesitate on donepezil in a frail older adult, or in someone with heart block or sick sinus. In those settings, memantine may be a safer place to start if the disease has reached the moderate stage.

What tips the choice

For someone with mild Alzheimer's, donepezil is the practical option. Memantine isn't approved for that stage and the evidence for it there is weaker.

For someone with moderate to severe Alzheimer's, both are on the table, and combining them is common. A fixed dose product called Namzaric combines memantine and donepezil in one capsule, which can simplify a complicated medication list. If side effects on donepezil are a problem, memantine alone is a reasonable path. If someone is already stable on donepezil and enters the moderate stage, adding memantine is a standard step.

Heart rhythm history matters. In someone with symptomatic bradycardia, sick sinus, or a history of syncope, memantine avoids the vagal effects that donepezil can cause. Similarly, in someone with an active GI disorder or ongoing weight loss, memantine's better tolerability can tip the scale.

Kidney function matters for memantine. In moderate to severe kidney disease, the dose is halved. Donepezil doesn't need the same kind of renal adjustment.

Cost is generally not the deciding factor, since both are generic. Formularies and prior authorizations can still come into play, and families sometimes find one drug on their plan without hassle and the other with paperwork.

Expectations matter more than any of this. If a family understands that these medications offer modest, sometimes hard to see benefits, that decisions to continue or stop should be revisited over time, and that neither is a cure, the treatment relationship is much easier. If the expectation is that memory will come back, disappointment is close behind.

Common questions

Do these medications actually work? They work in the sense that trials show a real, measurable effect on cognitive scores and daily function, and that effect is modest. For some people it's noticeable to family and clinicians. For others it looks more like a slower decline than what was expected. Neither drug reverses the disease, and the benefit tends to fade as the disease progresses.

Can donepezil and memantine be taken together? Yes, and it's common in moderate to severe Alzheimer's. The combination has better evidence than either drug alone in that range. Namzaric is a single capsule that combines both, which some families prefer for simplicity.

Which one has fewer side effects? Memantine, on average. Donepezil's cholinergic effects on the gut and heart are the main issue. Memantine's most common side effects are dizziness and headache, and both often settle with a slower titration.

When should these medications be stopped? There isn't one right answer. Some families and clinicians continue them into late-stage disease. Others stop them when the person can no longer swallow safely, when side effects outweigh any perceived benefit, or when goals of care shift toward comfort. Stopping should be discussed with the prescriber, and it's usually done gradually rather than abruptly.

Are there newer disease-modifying options? Yes, and they're a separate conversation. Anti-amyloid antibodies like lecanemab (Leqembi) and donanemab (Kisunla) are approved for early Alzheimer's with confirmed amyloid pathology. They're aimed at slowing decline rather than treating symptoms, and they come with their own risks and monitoring requirements. Donepezil and memantine remain symptom-focused options that are used across a wider range of the disease.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes. This is not medical advice.

1. U.S. Food and Drug Administration. Donepezil prescribing information.
2. U.S. Food and Drug Administration. Memantine prescribing information.
3. MedlinePlus, U.S. National Library of Medicine.
4. National Institute on Aging. Alzheimer's disease medications.